31 Kryukov G V, Pennacchio L A, Sunyaev S R. Most rare missense alleles are deleterious in humans: implications for complex disease andassociation studies. Am J Hum Genet, 2007, 80: 727-739？？
[2]
32 Biesecker L G. Exome sequencing makes medical genomics a reality. Nat Genet, 2010, 42: 13-14？？
[3]
1 Gomaa A I, Khan S A, Toledano M B, et al. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol,2008, 14: 4300-4308？？
[4]
2 Nguyen V T, Law M G, Dore G J. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepat, 2009, 16: 453-463？？
[5]
3 Farazi P A, DePinho R A. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer, 2006, 6: 674-687？？
[6]
4 Yu M W, Chang H C, Liaw Y F, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J NatlCancer Inst, 2000, 92: 1159-1164
[7]
5 Krawczyk M, Müllenbach R, Weber S N, et al. Genome-wide association studies and genetic risk assessment of liver diseases. Nat RevGastroenterol Hepatol, 2010, 7: 669-681？？
[8]
6 Altshuler D, Pollara V J, Cowles C R, et al. An SNP map of the human genome generated by reduced representation shotgun sequencing.Nature, 2000, 407: 513-516？？
[9]
7 Kao J H, Chen P J, Chen D S. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: Epidemiologic andmolecular biological aspects. Adv Cancer Res, 2010, 108: 21-72？？
[10]
8 Kim Y J, Lee H S. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virusinfection. Intervirology, 2005, 48: 10-15？？
[11]
9 de Bakker P I, Yelensky R, Pe’er I, et al. Efficiency and power in genetic association studies. Nat Genet, 2005, 37: 1217-1223？？
[12]
10 International HapMap Consortium. A haplotype map of the human genome. Nature, 2005, 437: 1299-1320？？
[13]
11 International HapMap Consortium, Frazer K A, Ballinger D G, et al. A second generation human haplotype map of over 3.1 million SNPs.Nature, 2007, 449: 851-861
[14]
12 1000 Genomes Project Consortium, Durbin R M, Abecasis G R, et al. A map of human genome variation from population-scale sequencing.Nature, 2010, 467: 1061-1073？？
[15]
13 Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 sharedcontrols. Nature, 2007, 447: 661-678
[16]
14 Easton D F, Pooley K A, Dunning A M, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007,447: 1087-1093？？
[17]
15 http: //www.genome.gov/26525384
[18]
16 Van Noorden R, Ledford H, Mann A. New year, new science. Nature, 2011, 469: 12？？
[19]
17 Krawczyk M, Müllenbach R, Weber S N, et al. Genome-wide association studies and genetic risk assessment of liver diseases. Nat RevGastroenterol Hepatol, 2010, 7: 669-681？？
[20]
18 Bagchi A, Mills A A. The quest for the 1p36 tumor suppressor. Cancer Res, 2008, 68: 2551-2556？？
[21]
19 Li S P, Wang H Y, Li J Q, et al. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol,2001, 34: 840-849
[22]
20 Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell, 2007, 128: 459-475？？
[23]
21 Munirajan A K, Ando K, Mukai A, et al. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2by inducing apoptotic cell death. J Biol Chem, 2008, 283: 24426-24434
[24]
22 Schlisio S, Kenchappa R S, Vredeveld L C, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential1p36 tumor suppressor. Genes Dev, 2008, 22: 884-893？？
[25]
23 Hirokawa N, Takemura R. Biochemical and molecular characterization of diseases linked to motor proteins. Trends Biochem Sci, 2003, 28:558-565？？
[26]
24 Yang H W, Chen Y Z, Takita J, et al. Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deletedin neuroblastoma at chromosome 1p36.2. Oncogene, 2001, 20: 5075-5083
[27]
25 Yeh I T, Lenci R E, Qin Y, et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. HumGenet, 2008, 124: 279-285
[28]
26 Manolio T A. Genomewide association studies and assessment of the risk of disease. N Engl J Med, 2010, 363: 166-176？？
[29]
27 Kraft P, Wacholder S, Cornelis M C, et al. Beyond odds ratios—communicating disease risk based on genetic profiles. Nat Rev Genet, 2009, 10:264-269？？
[30]
28 Yuen M F, Tanaka Y, Fong D Y, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma inchronic hepatitis B. J Hepatol, 2009, 50: 80-88？？
[31]
29 Wong V W, Chan S L, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol,2010, 28: 1660-1665？？
[32]
30 Yang H I, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. JClin Oncol, 2010, 28: 2437-2444？？
